Clinical Trial Update: Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating the combination of oral vinorelbine and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer; the study is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Navelbine (vinorelbine)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Carcinoma Breast Stage IV | Phase 2 | Status: COMPLETED